0001104659-24-030157.txt : 20240301 0001104659-24-030157.hdr.sgml : 20240301 20240301204559 ACCESSION NUMBER: 0001104659-24-030157 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Waddill William D. CENTRAL INDEX KEY: 0001553338 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37852 FILM NUMBER: 24712594 MAIL ADDRESS: STREET 1: C/O CALITHERA BIOSCIENCES STREET 2: 343 OYSTER POINT BLVD, SUITE 200 CITY: SO. SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Protagonist Therapeutics, Inc CENTRAL INDEX KEY: 0001377121 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980505495 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560-1160 BUSINESS PHONE: (510) 474-0170 MAIL ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560-1160 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Therapeutics Inc DATE OF NAME CHANGE: 20130605 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Inc DATE OF NAME CHANGE: 20061002 4 1 tm247765-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-03-01 0 0001377121 Protagonist Therapeutics, Inc PTGX 0001553338 Waddill William D. C/O PROTAGONIST THERAPEUTICS, INC. 7707 GATEWAY BLVD., SUITE 140 NEWARK CA 94560-1160 1 0 0 0 1 Common Stock 2024-03-01 4 M 0 12975 6.09 A 24975 D Common Stock 2024-03-01 4 S 0 12975 31.34 D 12000 D Stock Option (right to buy) 6.09 2024-03-01 4 M 0 12975 0.00 D 2026-07-16 Common Stock 12975 0 D Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.46 to $31.99. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. These stock options are fully vested. /s/ Matthew Gosling, Attorney-in-Fact for William D. Waddill 2024-03-01